Rotow Reviews Key Updates on the Management of CNS Metastases in NSCLC

Season 11 Episode 1  ·  Aug 08, 2024, 08:48 PM

Headliner
Share
Subscribe

Dr Rotow discusses data that demonstrated the central nervous system activity of datopotamab deruxtecan and osimertinib in patients with NSCLC.

Share
Subscribe
Next
ASCO 2024 Plenary: NADINA Trial Neoadjuvant Ipi/Nivo vs Adjuvant Nivo for Resectable Stage III Melanoma
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air